ERBB2 and neoplasm: The population of HER2-low patients with IHC 1 + and IHC 2 + with negative results on ISH grew from the primary tumor to recurrent disease and from recurrent disease to secondary metastasis in the entire study population (HER2-low: 39.3–47.0% − 47.2%).